An X-ray look at GPCR structure
UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Uta Mommert contributed 243 entries already.
UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.
After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have on the economy, research and politics. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.
UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.
Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.
European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.
Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.
Finding a treatment for depression that is well-tolerated and effective is difficult and time-consuming. UK scientists have now developed a blood test to predict whether common antidepressants will work in a patient.
Funded with €9m by the French government, biomaterial player Global Bioenergies is getting closer to its goal to build the first bio-isobutene plant. IBN-One, sugar beet producer Cristal Union and cosmetics giant L’Oreal are also on board.
A few months ago, the EMA introduced its new accelerated access scheme, PRIME. Now, the agency has published the first few therapies that will use the chance to speed their breakthrough meds through the approval process.

